Abstract
OBJECTIVE: To develop an assay for the measurement of this anti-human beta2-glycoprotein I a-beta2-GPI
METHODS: This study was conducted from September 2004 to December 2006. The patients attending the Rheumatology Clinic were chosen from several centers in the Eastern region of Saudi Arabia because they had complications. An enzyme-linked immunosorbent ELISA assay was optimized and developed to measure IgG a-beta2-GPI antibody levels in humans. Fifty normal blood donors and 50 systemic lupus erythrematosis SLE patients were selected for this experiment.
RESULTS: Raised IgG a-beta2-GPI antibody levels were found in 80% of SLE patients. Interestingly, raised IgG a-beta2-GPI antibody levels were associated with the presence of venous thrombosis and thrombocytopenia.
CONCLUSION: The real value of IgG a-beta2-GPI as a predictor for the future clinical complications needs to be confirmed in prospective controlled studies investigating clinical complications in relationship to IgG a-beta2-GPI and to other risk factors for thrombosis.
- Copyright: © Saudi Medical Journal
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.